Alzheimer’s Disease/Dementia News

Healio Psychiatry’s five most-viewed stories of the year highlight a study on omega-3 supplementation and stress-related accelerated aging, research into the benefits of cannabidiol for frontline health care workers and data on the link between OCD and increased risk for dementia/Alzheimer’s disease.

The FDA has granted fast track designation for lecanemab, an investigational antiamyloid beta protofibril antibody used for treatment of patients in the early stages of Alzheimer’s disease.

Identifying and addressing risk factors for cognitive disorders shared within couples may reduce the risk for these disorders in the spouses of those with dementia, according to results of a prospective cohort study in JAMA Network Open.

Biogen Inc. and Eisai Co. Ltd. announced plans to submit their phase 4 protocol for Aduhelm to the FDA in March 2022.

Clonal hematopoiesis of indeterminate potential, which has been shown to substantially increase risk for blood cancer and cardiovascular disease, also appeared associated with protection from Alzheimer’s disease, according to study results.

A self-administered test detected mild cognitive impairment conversion to dementia at least 6 months sooner than the Mini-Mental State Examination, according to results of a cohort study published in Alzheimer’s Research & Therapy.

Nearly 50% of individuals with incident mild cognitive impairment diagnoses were considered cognitively normal at follow-up, according to results of a community-based cohort study published in Neurology.

Phase 3 studies of Aduhelm showed amyloid-related imaging abnormalities among approximately 40% of participants, according to study results published in JAMA Neurology.

Intensive blood pressure reduction did not appear to prevent cognitive decline and dementia, according to results of a systematic review and meta-analysis published in JAMA Network Open.

Healio Psychiatry’s five most-viewed stories in November highlight the link between alopecia areata and dementia risk, a blood test that may identify Alzheimer’s disease symptoms, and regulatory developments.